PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1192
https://www.valueinhealthjournal.com/article/S1098-3015(11)02754-9/fulltext
Title :
PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02754-9&doi=10.1016/j.jval.2011.08.1192
First page :
A450
Section Title :
Cancer
Open access? :
No
Section Order :
1149